Patent Disputes Over COVID-19 Vaccines Expose Systemic Inequities in Global Health Governance
Original framing: “CureVac sues Moderna for patent infringement over COVID-19 vaccines - Reuters” — Reuters (via Google News)
The original framing omits the historical context of patent disputes over vaccines, the perspectives of low- and middle-income countries, and the structural causes of health inequities. It also neglects to consider the role of pharmaceutical companies in shaping global health policies and the need for a more equitable and transparent global health governance system.
Low structural omission detected in mainstream coverage.
This narrative was produced by Reuters, a Western news agency, for a global audience, serving the interests of pharmaceutical companies and Western governments while obscuring the perspectives of low- and middle-income countries. The framing reinforces the dominant Western discourse on intellectual property rights and global health governance.
Patent disputes over vaccines have a long history, dating back to the 19th century. The development of vaccines has always been a complex process involving multiple stakeholders, including pharmaceutical companies, governments, and civil society organizations. A deeper understanding of these historical patterns is essential to addressing the complexities of global health governance.
The patent dispute between CureVac and Moderna highlights the need for a more equitable and transparent global health governance system.